Breast cancer
Explore our latest news, features and educational resources in this specialist area.
SMC accepts treatment for breast cancer
Pertuzumab/trastuzumab is accepted for restricted use within NHS Scotland in line with previous SMC advice for pertuzumab and trastuzumab.
Drug Safety Update: CDK4/6 inhibitors
The MHRA has warned of reports of interstitial lung disease and pneumonitis, including severe cases, with CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼)
Abemaciclib not recommended for advanced breast cancer
Treatment will be removed from the CDF on publication of the final guidance if the draft recommendation does not change following public consultation.
Regulatory Alerts, Cancer, Oncology, Breast cancer, Gastrointestinal cancer, Head and neck cancer, Oncology Room
5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
Patients with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with these medicines.